US · LQDA · MEDICAL - PHARMACEUTICALS
Liquidia Corporation (LQDA) intrinsic value and stock valuation
$54.43as of 2026-11-21 · Mkt cap 7.93B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Liquidia Corporation DCF and intrinsic value
InvestorsCraft values LQDA with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from LQDA’s statements →
Liquidia Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $158.3M | $14M | $17.5M | $15.9M | $12.9M |
| Operating income | -$-51.38M | -$-121.29M | -$-73.38M | -$-38.77M | -$-33.8M |
| Net income | -$-68.92M | -$-130.39M | -$-78.5M | -$-41.02M | -$-34.58M |
| EPSd | -$-800.84K | -$-1.66M | -$-1.21M | -$-672.9K | -$-696.05K |
| Operating cash flow | -$-35.69M | -$-93.42M | -$-41.56M | -$-28.59M | -$-34.03M |
| Capital expenditure | -$-4.34M | -$-4.95M | -$-1.29M | -$-590K | -$-110K |
| Free cash flow | -$-40.02M | -$-98.37M | -$-42.85M | -$-29.18M | -$-34.14M |
| Total assets | $327.9M | $230.3M | $118.3M | $129.2M | $93.7M |
| Total debt | $197.9M | $122.4M | $49.5M | $24.5M | $16.1M |
| Net debt | $7.25M | -$-54.09M | -$-34.14M | -$-68.82M | -$-41.41M |
| Total equity | $44.8M | $77.3M | $47.3M | $90.4M | $65.3M |
| Cash and short-term investments | $190.7M | $176.5M | $83.7M | $93.3M | $57.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $158.3M | $14M | $17.5M | $15.9M | $12.9M |
| Cost of revenue | $13.2M | $5.88M | $2.89M | $2.86M | $3.02M |
| Gross profit | $145.1M | $8.12M | $14.6M | $13.1M | $9.83M |
| Research and development expenses | $39.3M | $47.8M | $43.2M | $19.4M | $20.5M |
| Selling, general and administrative expenses | $157.2M | $81.6M | $44.7M | $32.4M | $23.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $196.5M | $129.4M | $88M | $51.9M | $43.6M |
| Cost and expenses | $209.7M | $135.3M | $90.9M | $54.7M | $46.7M |
| Interest income | $6.62M | $7.65M | $3.47M | $1.09M | $30K |
| Interest expense | $24.2M | $12.5M | $6.27M | $2.34M | $760K |
| Depreciation and amortization | $1.53M | $2.2M | $2.18M | $3.65M | $5.61M |
| Ebitda | -$-43.22M | -$-115.71M | -$-70.05M | -$-35.03M | -$-28.2M |
| Operating income | -$-51.38M | -$-121.29M | -$-73.38M | -$-38.77M | -$-33.8M |
| Total other income/expenses, net | -$-17.55M | -$-9.1M | -$-5.12M | -$-2.25M | -$-780K |
| Income before tax | -$-68.92M | -$-130.39M | -$-78.5M | -$-41.02M | -$-34.58M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-68.92M | -$-130.39M | -$-78.5M | -$-41.02M | -$-34.58M |
| Weighted average shares outstanding | $86.1M | $78.7M | $65M | $61M | $49.7M |
| Weighted average diluted shares outstanding | $86.1M | $78.7M | $65M | $61M | $49.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $190.7M | $176.5M | $83.7M | $93.3M | $57.5M |
| Net receivables | $54.1M | $2.72M | $4.06M | $5.02M | $2.99M |
| Inventory | $0.00 | $240K | $0.00 | $0.00 | $0.00 |
| Total current assets | $190.7M | $185.1M | $89.9M | $99.8M | $61.3M |
| Property, plant and equipment, net | $0.00 | $12.5M | $6.18M | $6.25M | $7.43M |
| Goodwill and intangible assets | $6.86M | $7.06M | $7.33M | $7.63M | $8.29M |
| Long-term investments | $3.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $137.3M | $45.2M | $28.4M | $29.4M | $32.5M |
| Total assets | $327.9M | $230.3M | $118.3M | $129.2M | $93.7M |
| Accounts payable | $3.68M | $4.69M | $1.4M | $2.2M | $1.07M |
| Short-term debt | $58.9M | $18.4M | $3.75M | $1.08M | $1.09M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $135.8M | $41.8M | $18.6M | $8.8M | $7.33M |
| Long-term debt | $139M | $104M | $45.8M | $23.4M | $15M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $147.4M | $111.3M | $52.5M | $30M | $21.1M |
| Capital lease obligations | $6.59M | $7M | $3.5M | $4.58M | $5.67M |
| Total liabilities | $283.2M | $153M | $71M | $38.8M | $28.5M |
| Common stock | $90K | $90K | $70K | $60K | $50K |
| Retained earnings | -$-626.31M | -$-559.49M | -$-429.1M | -$-350.6M | -$-309.58M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $44.8M | $77.3M | $47.3M | $90.4M | $65.3M |
| Total investments | $3.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $197.9M | $122.4M | $49.5M | $24.5M | $16.1M |
| Net debt | $7.25M | -$-54.09M | -$-34.14M | -$-68.82M | -$-41.41M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-68.92M | -$-130.39M | -$-78.5M | -$-41.02M | -$-34.58M |
| Depreciation and amortization | $1.53M | $2.2M | $2.18M | $3.65M | $5.61M |
| Stock-based compensation | $29.5M | $18.8M | $10.1M | $9.3M | $6.75M |
| Change in working capital | -$-24.18M | -$-4.79M | $5.87M | -$-2.16M | -$-12.38M |
| Accounts receivable | -$-51.37M | $1.34M | $960K | -$-2.03M | -$-2.99M |
| Inventory | -$-22.99M | -$-240K | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.59M | $2.33M | -$-1.15M | $810K | -$-7.56M |
| Net cash provided by operating activities | -$-35.69M | -$-93.42M | -$-41.56M | -$-28.59M | -$-34.03M |
| Investments in property, plant and equipment | -$-4.34M | -$-4.95M | -$-1.29M | -$-590K | -$-110K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $10K | $0.00 |
| Net cash used for investing activities | -$-6.34M | -$-8.44M | -$-11.29M | -$-590K | -$-110K |
| Common stock issued | $4.82M | $138.6M | $24.2M | $54.5M | $21.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $59.7M | $194.7M | $43.3M | $65M | $26.3M |
| Net change in cash | $14.2M | $92.8M | -$-9.6M | $35.8M | -$-7.82M |
| Cash at end of period | $190.7M | $176.5M | $83.7M | $93.3M | $57.5M |
| Operating cash flow | -$-35.69M | -$-93.42M | -$-41.56M | -$-28.59M | -$-34.03M |
| Capital expenditure | -$-4.34M | -$-4.95M | -$-1.29M | -$-590K | -$-110K |
| Free cash flow | -$-40.02M | -$-98.37M | -$-42.85M | -$-29.18M | -$-34.14M |
Line items
Line items
Line items
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
- CEO
- Roger A. Jeffs
- Employees
- 216
- Beta
- 0.55
Explore
Frequently asked questions
What is the intrinsic value of Liquidia Corporation (LQDA)?
Liquidia Corporation (LQDA) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LQDA undervalued?
LQDA trades at a price of $54.43 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.